Insulin secretion and insulin sensitivity in diabetic and non-diabetic subjects with hepatic nuclear factor-1alpha (maturity-onset diabetes of the young-3) mutations

CNRS EP-10, Institut Pasteur de Lille, Lille, France.

OBJECTIVE: To evaluate insulin secretion and sensitivity in affected (diabetes mellitus or impaired glucose tolerance; n=7) and in unaffected (normal glucose tolerance; n=3) carriers of hepatocyte nuclear factor-1alpha (maturity-onset diabetes of the young-3 (MODY3)) gene mutations. METHODS: Insulin secretion was assessed by an i.v. glucose tolerance test (IVGTT), hyperglycemic clamp and arginine test, and insulin sensitivity by an euglycemic hyperinsulinemic clamp. Results were compared with those of diabetic MODY2 (glucokinase-deficient) and control subjects. RESULTS: The amount of insulin secreted during an IVGTT was decreased in affected MODY3 subjects (46+/-24 (s.d.) pmol/kg body weight (BW)) as compared with values in MODY2 (120+/-49pmol/kg BW) and control (173+/-37pmol/kg BW; P=0.0004) subjects. The amount of insulin secreted during a 10mmol/l glucose clamp was decreased in affected MODY3 subjects (171+/-78pmol/kg BW) and MODY2 subjects (302+/-104pmol/kg BW) as compared with control subjects (770+/-199pmol/kg BW; P=0.0001). Insulin secretion in response to arginine was decreased in affected MODY3 subjects. Milder and heterogeneous defects were observed in the unaffected MODY3 subjects; the amount of insulin secreted during the hyperglycemic clamp was 40-79% of that of controls. The response to arginine was abnormally delayed. Insulin sensitivity was decreased in diabetic but not in non-diabetic MODY3 subjects. CONCLUSIONS: Beta-cell dysfunction in response to glucose and arginine is observed in affected and unaffected MODY3 subjects. The MODY3 and MODY2 subtypes present different insulin secretion profiles. Secondary insulin resistance might contribute to the chronic hyperglycemia of MODY3 patients and modulate their glucose tolerance.

This article has been cited by other articles:

				M. Vaxillaire and P. Froguel Monogenic Diabetes in the Young, Pharmacogenetics and Relevance to Multifactorial Forms of Type 2 Diabetes Endocr. Rev., May 1, 2008; 29(3): 254 - 264. [Abstract] [Full Text] [PDF]

				T. Tuomi, E. H. Honkanen, B. Isomaa, L. Sarelin, and L. C. Groop Improved Prandial Glucose Control With Lower Risk of Hypoglycemia With Nateglinide Than With Glibenclamide in Patients With Maturity-Onset Diabetes of the Young Type 3 Diabetes Care, February 1, 2006; 29(2): 189 - 194. [Abstract] [Full Text] [PDF]

				A. Brackenridge, E. R. Pearson, F. Shojaee-Moradie, A. T. Hattersley, D. Russell-Jones, and A. M. Umpleby Contrasting Insulin Sensitivity of Endogenous Glucose Production Rate in Subjects With Hepatocyte Nuclear Factor-1{beta} and -1{alpha} Mutations Diabetes, February 1, 2006; 55(2): 405 - 411. [Abstract] [Full Text] [PDF]

				A. Stride, S. Ellard, P. Clark, L. Shakespeare, M. Salzmann, M. Shepherd, and A. T. Hattersley {beta}-Cell Dysfunction, Insulin Sensitivity, and Glycosuria Precede Diabetes in Hepatocyte Nuclear Factor-1{alpha} Mutation Carriers Diabetes Care, July 1, 2005; 28(7): 1751 - 1756. [Abstract] [Full Text] [PDF]

				Y. Reznik, T. Dao, R. Coutant, L. Chiche, E. Jeannot, S. Clauin, P. Rousselot, M. Fabre, F. Oberti, A. Fatome, et al. Hepatocyte Nuclear Factor-1{alpha} Gene Inactivation: Cosegregation between Liver Adenomatosis and Diabetes Phenotypes in Two Maturity-Onset Diabetes of the Young (MODY)3 Families J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1476 - 1480. [Abstract] [Full Text] [PDF]

				H. Wang, K. Hagenfeldt-Johansson, L. A. Otten, B. R. Gauthier, P. L. Herrera, and C. B. Wollheim Experimental Models of Transcription Factor-Associated Maturity-Onset Diabetes of the Young Diabetes, December 1, 2002; 51(90003): S333 - 342. [Abstract] [Full Text] [PDF]